Abstract
Neuroleptic malignant syndrome (NMS) is a severe complication of antipsychotics, especially those of first generation such as haloperidol, which was the first in which this pathology was described, characterized by: fever, rigidity, alteration of the state of consciousness and dysautonomies. On the other side, central pontine myelinolysis (Now Called Osmotic Demyelination Syndrome), search results of acute sodium alterations of sodium, as those occurring in hyponatremia replenings and could put life at risk just like the NMS. The association of these two pathologies is unusual and until now, their causal relationship, the result of the few cases reported, is not clearly known. Although the relationship of the neurological syndrome may be limited, the company of central myelolysis could increase the morbidity of this entity, so it is necessary to be required quickly to prevent the onset of complications, which does not have a specific treatment. We present the case of a young patient who has these pathologies and we consider that the cause of centralized myelinolysis is haloperidol as well as NMS, despite this, this medication continues to be very safe in clinical practice since the appearance of These complications is an idiosyncratic reaction due to some type of unknown genetic susceptibility.
References
Delay J, Pichot P, Lemperiere T, Elissalde B, Peigne F. A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses. Ann Med Psychol (París). 1960;118(1):145-52.
Tse L, Barr AM, Scarapicchia V, Vila-Rodriguez F. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol. 2015;13(3):395-406. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/26411967%5Cnhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812801/pdf/CN-13-395.pdf
Pileggi DJ, Cook AM. Neuroleptic malignant syndrome: focus on treatment and rechallenge. Ann. Pharmacother. 2016;50(11):973-81.
Pedraza OL, Zarco L, Sánchez E, Ruiz C, Coral J, Charry P. Síndrome de desmielinización osmótica posttransplante hepático: a propósito de un caso. Acta Neurol Colomb. 2007;23(40):19-24.
Vilalta-Franch J, López-Pousa S, Garre-Olmo J. Mortalidad en pacientes con enfermedad de Alzheimer tratados con neurolépticos atípicos. Rev Neurol. 2008;46(3):129-34.
Bascuñana H, Villarreal I, Alfonso S, Bernabeu M, Terré R. Agitación en el traumatismo craneoencefálico I. Definición y tratamiento con neurolépticos, ansiolíticos y antiepilépticos. Rev Neurol. 2000;30(9):850-4.
Andreu-Giménez L, Robert-Gates J, Jover-Díaz F, Pagán-Acosta G, Merino-Sánchez J. Catatonía letal y su diferenciación del síndrome neuroléptico maligno. Rev Neurol. 2002;34(4):399-400.
Levenson L. Neuroleptic malignant syndrome. Am J Psychiatry. 1985;142(10):1137-45.
Wu Y-F, Kan Y-S, Yang C-H. Neuroleptic malignant syndrome associated with bromocriptine withdrawal in Parkinson's disease a case report. Gen Hosp Psychiatry. 2011;33(3):301. e7-301.e8.
Serrano-Dueñas M. Neuroleptic malignant syndrome-like, or-dopaminergic malignant syndrome-due to levodopa therapy withdrawal. Clinical features in 11 patients. Parkinsonism Relat Disord. 2003;9(3):175-8.
Gurrera RJ, Mortillaro G, Velamoor V, FRCP C, Caroff SN. A validation study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome. J Clin Psychopharmacol. 2017;37(1):67-71.
Carrillo de Albornoz CM, Guerrero-Jiménez M, Gutiérrez-Rojas L. Mielinólisis central pontina inducida por antipsicóticos en un sujeto con hiperplasia suprarrenal congénita. Hiperexcit-abilidad nerviosa en el síndrome de Michaelis-Manz. Revista de Neurología. 2017;64(5):235-6.
González-Aguilar A, Carrillo-Mezo R, Santos Zambrano J. Signo del mono en la mielinólisis pontina. Rev Neurol. 2009;48(6):331-2.
Vargas MI, Kohler R, Lovblad K, Delavelle J. Mielinolisis central pontina: Criterios diagnosticos en resonancia magnetica. Rev Neurol. 2009;48(12):654-5.
Francis A, Chandragiri S, Rizvi S, Koch M PG. Is lorazepam a treatment for neuroleptic malignant syndrome? CNS Spectr. 2000;5(7):54-7.
Nagel M, Freisberg S, Junghanns K, Moll CKE, Willenborg B. Das maligne neuroleptische Syndrom (MNS) - Eine system-atische Ubersicht. Fortschr Neurol Psychiatr. 2015;83(7):373-80.
Reulbach U, Dütsch C, Biermann T, Sperling W Thuerauf N, Kornhuber J, et al. Managing an effective treatment for neuro-leptic malignant syndrome. Crit Care (Londres). 2007;11(1):R4. Disponible en: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid-2151884&tool-pmcentrez&rendertype-abstract
Modi S, Dharaiya D, Schultz L VP. Neuroleptic malignant syndrome: complications, outcomes, and mortality. Neurocrit Care. 2016;24(1):97-103.
Nakamura M, Yasunaga H, Miyata H, Shimada T, Horiguchi H. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. J Clin Psychiatry. 2012;73(4):427-30.
Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome. An 11-year longitudinal case control study. Can J Psychiatry. 2012;57(8):512-8. Disponible en: http://link.springer.com/10.2165/00128415-201214070-00038
Tural Ü, Onder E. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death. Psychiatry Clin Neurosci. 2010;64(1):79-87.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.